 Intensive chemotherapy induction interferon-alpha maintenance patients Philadelphia chromosome-positive chronic myelogenous leukemia pilot study patients Philadelphia chromosome-positive chronic myelogenous leukemia intensive chemotherapy induction interferon-alpha IFN-A maintenance Intensive chemotherapy cycles daunorubicin day cytarabine days mg day mg days DOAP Maintenance therapy IFN-A doses daily counts toxicity outcome patients matched historic population patients IFN-A Overall patients cytogenetic response partial complete induction chemotherapy cytogenetic response IFN-A maintenance median follow-up months survival rate patients matched historic group incidence lymphoid blastic transformation groups durable cytogenetic responses summary addition intensive chemotherapy induction IFN-A maintenance survival rate incidence lymphoid blastic transformation incidence durable cytogenetic response results IFN-A therapy